APNHY
Price
$5.98
Change
+$0.43 (+7.75%)
Updated
Aug 27 closing price
Capitalization
2.69B
BIOVF
Price
$30.75
Change
+$1.78 (+6.14%)
Updated
Aug 22 closing price
Capitalization
10.54B
Interact to see
Advertisement

APNHY vs BIOVF

Header iconAPNHY vs BIOVF Comparison
Open Charts APNHY vs BIOVFBanner chart's image
Aspen Pharmacare Holdings
Price$5.98
Change+$0.43 (+7.75%)
Volume$1.49K
Capitalization2.69B
Swedish Orphan Biovitrum AB
Price$30.75
Change+$1.78 (+6.14%)
Volume$243
Capitalization10.54B
APNHY vs BIOVF Comparison Chart in %
Loading...
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APNHY vs. BIOVF commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and BIOVF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (APNHY: $5.98 vs. BIOVF: $30.75)
Brand notoriety: APNHY and BIOVF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: APNHY: 38% vs. BIOVF: 80%
Market capitalization -- APNHY: $2.69B vs. BIOVF: $10.54B
APNHY [@Pharmaceuticals: Generic] is valued at $2.69B. BIOVF’s [@Pharmaceuticals: Generic] market capitalization is $10.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APNHY’s FA Score shows that 1 FA rating(s) are green whileBIOVF’s FA Score has 0 green FA rating(s).

  • APNHY’s FA Score: 1 green, 4 red.
  • BIOVF’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOVF is a better buy in the long-term than APNHY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APNHY’s TA Score shows that 4 TA indicator(s) are bullish while BIOVF’s TA Score has 5 bullish TA indicator(s).

  • APNHY’s TA Score: 4 bullish, 6 bearish.
  • BIOVF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BIOVF is a better buy in the short-term than APNHY.

Price Growth

APNHY (@Pharmaceuticals: Generic) experienced а -4.32% price change this week, while BIOVF (@Pharmaceuticals: Generic) price change was +6.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.00%. For the same industry, the average monthly price growth was +11.42%, and the average quarterly price growth was +84.24%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.00% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOVF($10.5B) has a higher market cap than APNHY($2.69B). BIOVF has higher P/E ratio than APNHY: BIOVF (23.31) vs APNHY (10.61). BIOVF YTD gains are higher at: 11.171 vs. APNHY (-27.603). BIOVF has higher annual earnings (EBITDA): 9.77B vs. APNHY (8.02B). APNHY has more cash in the bank: 6.8B vs. BIOVF (1.06B). BIOVF has less debt than APNHY: BIOVF (12.8B) vs APNHY (35.5B). APNHY has higher revenues than BIOVF: APNHY (45.5B) vs BIOVF (27B).
APNHYBIOVFAPNHY / BIOVF
Capitalization2.69B10.5B26%
EBITDA8.02B9.77B82%
Gain YTD-27.60311.171-247%
P/E Ratio10.6123.3146%
Revenue45.5B27B169%
Total Cash6.8B1.06B643%
Total Debt35.5B12.8B277%
FUNDAMENTALS RATINGS
APNHY vs BIOVF: Fundamental Ratings
APNHY
BIOVF
OUTLOOK RATING
1..100
5894
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
9965
PRICE GROWTH RATING
1..100
9052
P/E GROWTH RATING
1..100
9491
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APNHY's Valuation (9) in the null industry is significantly better than the same rating for BIOVF (80). This means that APNHY’s stock grew significantly faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (49) in the null industry is somewhat better than the same rating for APNHY (100). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's SMR Rating (65) in the null industry is somewhat better than the same rating for APNHY (99). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's Price Growth Rating (52) in the null industry is somewhat better than the same rating for APNHY (90). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's P/E Growth Rating (91) in the null industry is in the same range as APNHY (94). This means that BIOVF’s stock grew similarly to APNHY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APNHYBIOVF
RSI
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
52%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
47%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
44%
Advances
ODDS (%)
Bullish Trend 17 days ago
66%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
59%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
48%
Aroon
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPUS122.950.53
+0.43%
JPMorgan Diversified Return US Eq ETF
SPYX53.220.12
+0.22%
SPDR® S&P 500 Fossil Fuel Rsrv Free ETF
HTAX23.470.03
+0.11%
Macquarie National High-Yield Municipal Bond ETF
TBX28.22-0.04
-0.14%
ProShares Short 7-10 Year Treasury
MFEM21.69-0.12
-0.55%
PIMCO RAFI Dyn Mlt-Fctr Emrg Mkts Eq ETF

APNHY and

Correlation & Price change

A.I.dvisor tells us that APNHY and TRUFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TRUFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APNHY
1D Price
Change %
APNHY100%
+7.75%
TRUFF - APNHY
21%
Poorly correlated
+3.21%
PRFX - APNHY
20%
Poorly correlated
-1.23%
ESALF - APNHY
20%
Poorly correlated
N/A
SDZNY - APNHY
20%
Poorly correlated
+1.18%
BIOVF - APNHY
19%
Poorly correlated
N/A
More

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and INNPF have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and INNPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
N/A
INNPF - BIOVF
20%
Poorly correlated
+0.25%
APNHY - BIOVF
19%
Poorly correlated
+7.75%
BIOGY - BIOVF
11%
Poorly correlated
N/A
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
More